| Literature DB >> 30417882 |
Jenny L Carey1, Olivia H Cox1, Fayaz Seifuddin1, Leonard Marque1, Kellie L K Tamashiro1, Peter P Zandi2, Gary S Wand3, Richard S Lee4.
Abstract
As genomes of a wider variety of animals become available, there is an increasing need for tools that can capture dynamic epigenetic changes in these animal models. The rat is one particular model animal where an epigenetic tool can complement many pharmacological and behavioral studies to provide insightful mechanistic information. To this end, we adapted the SureSelect Target Capture System (referred to as Methyl-Seq) for the rat, which can assess DNA methylation levels across the rat genome. The rat design targeted promoters, CpG islands, island shores, and GC-rich regions from all RefSeq genes. To implement the platform on a rat experiment, male Sprague Dawley rats were exposed to chronic variable stress for 3 weeks, after which blood samples were collected for genomic DNA extraction. Methyl-Seq libraries were constructed from the rat DNA samples by shearing, adapter ligation, target enrichment, bisulfite conversion, and multiplexing. Libraries were sequenced on a next-generation sequencing platform and the sequenced reads were analyzed to identify DMRs between DNA of stressed and unstressed rats. Top candidate DMRs were independently validated by bisulfite pyrosequencing to confirm the robustness of the platform. Results demonstrate that the rat Methyl-Seq platform is a useful epigenetic tool that can capture methylation changes induced by exposure to stress.Entities:
Mesh:
Year: 2018 PMID: 30417882 PMCID: PMC6235597 DOI: 10.3791/58617
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355





|
| Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 |
| AM | Restraint | Swim | Cold Room | Swim | Restraint | Shaker | Swim |
| PM | Shaker | Cage Tilt | Restraint | Shaker | Cold Room | Restraint | Cold Room |
| Overnight | Food Restrict | Wet Bedding | Isolation | Light On | Crowding | Light On | Wet Bedding |
|
|
|
|
|
|
| |
| Paired End Reads (PER) | 89,290,397 | 80,165,674 |
| Uniquely Mapped Paired End Reads (UMPER) | 39,200,255 | 35,013,406 |
| Alignment Rate/Mapping Efficiency (UMPER/PER) | 44% | 44% |
| Duplicate Reads (% of UMPER) | 73% | 65% |
| Deduplicated UMPER | 10,481,031 | 12,306,018 |
| Average Read Depth Coverage (x) (ARDC) | 6x | 6x |
| CpGs (N) | 12,056,878 | 12,056,878 |
| ARDC (x) of CpGs | 2x | 2x |
| CpGs with at least 10 reads (N) | 481,383 | 595,850 |
| ARDC (X) of CpGs with at least 10 reads | 19 | 19 |
| On Target CpGs (complete overlap with Probe Target Regions) | 1,923,872 | 2,007,638 |
| On Target ARDC (x) of CpGs | 7x | 8x |
| On Target CpGs with at least 10 reads (N) | 428,249 | 531,419 |
| On Target ARDC (x) of CpGs with at least 10 reads | 18x | 18x |
| On Target (PER with 1 or more Base Pair overlap with Probe Target Regions) (UMPER) | 8,277,715 | 9,369,523 |
| % On Target (of Deduplicated UMPER) | 78% | 77% |
| On Target (Total Bases Mapped) Mb | 125 Mb | 128 Mb |
| On Target Average Read Depth Coverage (x) (ARDC) | 9x | 10x |
| 1Sequencing metrics based on averages across subjects in each group |
|
|
|
|
|
|
|
|
|
|
|
| chr20 | 1,644,246 | 1,644,390 | RT1-M4 | in_gene | 93.03 | 0.22 | 0.33 | 0.11 | gain |
| chr5 | 160,361,352 | 160,361,564 | LOC690911 | in_gene | -70.75 | -0.19 | 0.72 | 0.91 | loss |
| chr3 | 61,138,281 | 61,138,330 | RGD1564319 | 265569 | 61.79 | 0.21 | 0.94 | 0.72 | gain |
| chr2 | 143,064,811 | 143,065,010 | Ufm1 | 8569 | -59.48 | -0.11 | 0.13 | 0.24 | loss |
| chr7 | 30,764,111 | 30,764,284 | Ntn4 | in_gene | 57.04 | 0.21 | 0.94 | 0.73 | gain |
| chr17 | 12,469,112 | 12,469,218 | Idnk | 41996 | -50.91 | -0.13 | 0.74 | 0.88 | loss |
| chr7 | 47,101,725 | 47,101,930 | Pawr | in_gene | -50.54 | -0.12 | 0.64 | 0.76 | loss |
| chr5 | 76,111,248 | 76,111,822 | Txndc8 | 151703 | -50.38 | -0.11 | 0.85 | 0.96 | loss |
| chr11 | 80,640,132 | 80,640,356 | Dgkg | in_gene | -50.07 | -0.16 | 0.73 | 0.89 | loss |
| chr8 | 71,759,248 | 71,759,411 | Mir190 | 210226 | -47.84 | -0.17 | 0.58 | 0.75 | loss |
|
|
|
|
|
|
|
| ||||
| Type II diabetes mellitus | 12 | 0.1 | 3.6 x 10-4 | 9.8 x 10-3 |
|
| ||||
| Vascular smooth muscle contraction | 18 | 0.1 | 1.6 x 10-3 | 3.6 x 10-2 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 13 | 0.1 | 4.0 x 10-3 | 7.1 x 10-2 |
| Dilated cardiomyopathy | 14 | 0.1 | 7.6 x 10-3 | 1.2 x 10-1 |
|
| ||||
| Long-term potentiation | 11 | 0.1 | 1.5 x 10-2 | 1.4 x 10-1 |
|
| ||||
| MAPK signaling pathway | 35 | 0.2 | 2.4 x 10-4 | 9.9 x 10-3 |
| Calcium signaling pathway | 22 | 0.1 | 1.2 x 10-2 | 1.4 x 10-1 |
| Chemokine signaling pathway | 21 | 0.1 | 1.2 x 10-2 | 1.3 x 10-1 |
|
| ||||
| Pathways in cancer | 42 | 0.3 | 4.1 x 10-5 | 3.4 x 10-3 |
| Glioma | 15 | 0.1 | 4.4 x 10-5 | 2.4 x 10-3 |
| Non-small cell lung cancer | 10 | 0.1 | 7.9 x 10-3 | 1.1 x 10-1 |
| Colorectal cancer | 13 | 0.1 | 8.4 x 10-3 | 1.1 x 10-1 |
| Chronic myeloid leukemia | 12 | 0.1 | 1.2 x 10-2 | 1.3 x 10-1 |